Florent Grange
Florent Grange has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Amir Khammari
Department of Dermatology, CHU Nantes, CIC 1413, INSERM UMR 1302/EMR6001 INCIT, Nantes University, Nantes, France
1 shared publication - Candice Lesage
Centre Hospitalier Universitaire de Montpellier 11
1 shared publication - Caroline Gaudy-Marqueste
Dermatology and Skin Cancer Department Aix Marseille University Marseille Cedex 07 France
1 shared publication - Charles Dolladille
University of Caen Normandy, Pharmacology Department, Centre Hospitalier Universitaire de Caen, Caen, France
1 shared publication - Eve Maubec
Department of Dermatology, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Paris Nord University, Bobigny, France; INSERM UMR 1124, Université Paris Cité, Paris, France
1 shared publication - Florence Brunet-Possenti
Department of Dermatology, Hôpital Bichat AP-HP, Université Paris Cité, 75018 Paris, France
1 shared publication
Latest Publications
- Open Access
- 18 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
Combined immune-related adverse events and prognosis in advanced melanoma patients treated with immune checkpoint inhibitors: VigiBase and RIC-Mel data analysis
IrAEs induced by Immune Checkpoints Inhibitors (ICIs) should improve survival, however the impact of multiple and severe irAEs on treatment response remains unclear. This study aimed to assess the association between irAEs pairs and response in melanoma patients. It was a retrospective observational study using the global database VigiBase, and the french RIC-Mel cohort, including melanoma patients treated with ICIs: anti-CTLA-4 (ipilimumab), anti-PD-1 (nivolumab and pembrolizumab), and anti-LAG-3 (relatlimab), and who experienced at least one irAE. After identifying individual irAEs and their co-occurrences as pairs, their association with treatment response was assessed using logistic regression. We identified 31,981 ICIs-treated patients in VigiBase and 6,362 in RIC-Mel. At least one irAE occurred in 63% of VigiBase cases and 25% of RIC-Mel patients. Among patients with irAEs, 17% in VigiBase and 8% in RIC-Mel, respectively, had experienced at least two. Nearly 300 irAEs pairs were identified, most commonly involving cutaneous, gastrointestinal, endocrine, and musculoskeletal systems. Among patients with two or more irAEs, co-occurring irAEs were associated with a reduced likelihood of reported disease progression in VigiBase (significant for 8 pairs among both all cases and severe cases). In RIC-Mel, no significant associations were found, although about half of pairs with results suggested a potential likelihood of favorable treatment response, involving similar organ systems as in VigiBase. Our results suggest that the emergence of specific irAEs pairs might serve as composite markers of beneficial immune activation and therapeutic efficacy.
- 18 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
Open AccessCombined immune-related adverse events and prognosis in advanced melanoma patients treated with immune checkpoint inhibitors: VigiBase and RIC-Mel data analysis
IrAEs induced by Immune Checkpoints Inhibitors (ICIs) should improve survival, however the impact of multiple and severe irAEs on treatment response remains unclear. This study aimed to assess the association between irAEs pairs and response in melanoma patients. It was a retrospective observational study using the global database VigiBase, and the french RIC-Mel cohort, including melanoma patients treated with ICIs: anti-CTLA-4 (ipilimumab), anti-PD-1 (nivolumab and pembrolizumab), and anti-LAG-3 (relatlimab), and who experienced at least one irAE. After identifying individual irAEs and their co-occurrences as pairs, their association with treatment response was assessed using logistic regression. We identified 31,981 ICIs-treated patients in VigiBase and 6,362 in RIC-Mel. At least one irAE occurred in 63% of VigiBase cases and 25% of RIC-Mel patients. Among patients with irAEs, 17% in VigiBase and 8% in RIC-Mel, respectively, had experienced at least two. Nearly 300 irAEs pairs were identified, most commonly involving cutaneous, gastrointestinal, endocrine, and musculoskeletal systems. Among patients with two or more irAEs, co-occurring irAEs were associated with a reduced likelihood of reported disease progression in VigiBase (significant for 8 pairs among both all cases and severe cases). In RIC-Mel, no significant associations were found, although about half of pairs with results suggested a potential likelihood of favorable treatment response, involving similar organ systems as in VigiBase. Our results suggest that the emergence of specific irAEs pairs might serve as composite markers of beneficial immune activation and therapeutic efficacy.